Metronomic chemotherapy in patients with advanced neuroendocrine tumors: A single-center retrospective analysis.
capecitabine
metronomic chemotherapy
neuroendocrine
temozolomide
Journal
Journal of neuroendocrinology
ISSN: 1365-2826
Titre abrégé: J Neuroendocrinol
Pays: United States
ID NLM: 8913461
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
revised:
02
07
2022
received:
16
03
2022
accepted:
09
07
2022
entrez:
28
10
2022
pubmed:
29
10
2022
medline:
2
11
2022
Statut:
ppublish
Résumé
Neuroendocrine tumors (NETs) are more commonly slow-growing, therefore patients often receive chronic systemic therapies for tumor growth control and preservation of quality of life. Metronomic chemotherapy (mCT) is in line with this goal as it leads to stabilization of tumor growth over time without severe systemic toxicity. This is a retrospective analysis of patients with metastatic NETs receiving metronomic capecitabine (mCAP) or temozolomide (mTEM), at a NET-referral center. The aims of the study were to explore activity and safety of mCT and relationships between some characteristics of the patient population and clinical outcomes. Among a total of 67 patients with metastatic well or moderately differentiated (W/M-D) NETs, mostly gastroenteropancreatic (GEP) and nonfunctioning, 1.2 years (95% CI: 0.8-1.8) median progression-free survival (mPFS), and 3.0 years (95% CI: 2.3-4.9) median overall survival (mOS) were observed. Disease control rate was 85%. Grade 3 adverse events occurred in 15% of patients in mCAP and 13% in mTEM, and were mostly hematological and gastrointestinal. At univariate and multivariate analysis none of the variables analyzed (treatment regimen, sex, age at diagnosis, site of primary tumor and metastases, number of previous mCT lines, baseline tumor status before mCT, Ki67 value) were significantly correlated to OS and PFS. Our retrospective study suggested that mCAP and mTEM can be active and well tolerated in patients with metastatic W/M-D NETs, irrespective of the primary site, site of metastases, line of treatment and baseline tumor status.
Identifiants
pubmed: 36306196
doi: 10.1111/jne.13189
pmc: PMC9786253
doi:
Substances chimiques
Capecitabine
6804DJ8Z9U
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13189Informations de copyright
© 2022 The Authors. Journal of Neuroendocrinology published by John Wiley & Sons Ltd on behalf of British Society for Neuroendocrinology.
Références
Cancer Chemother Pharmacol. 2007 Apr;59(5):637-42
pubmed: 16937105
BMC Cancer. 2009 Nov 03;9:388
pubmed: 19886987
N Engl J Med. 2011 Feb 10;364(6):514-23
pubmed: 21306238
Bioessays. 1991 Jan;13(1):31-6
pubmed: 1722975
Nature. 2011 May 19;473(7347):298-307
pubmed: 21593862
Eur J Cancer. 2019 Mar;109:175-182
pubmed: 30735919
Lab Invest. 2012 Jul;92(7):952-66
pubmed: 22546866
BMC Cancer. 2014 Mar 14;14:184
pubmed: 24628963
Med Oncol. 2015 Mar;32(3):54
pubmed: 25638466
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
pubmed: 10655437
Clin Cancer Res. 2007 Jan 1;13(1):187-96
pubmed: 17200354
Cancer Res. 2007 Apr 15;67(8):3560-4
pubmed: 17440065
Endocr Relat Cancer. 2012 Jan 09;19(1):L1-4
pubmed: 22232542
Onco Targets Ther. 2014 Oct 20;7:1919-26
pubmed: 25364262
J Clin Oncol. 2008 Mar 10;26(8):1316-23
pubmed: 18323556
Angiogenesis. 2013 Apr;16(2):373-86
pubmed: 23143659
Histopathology. 2020 Jan;76(2):182-188
pubmed: 31433515
Lancet. 2016 Mar 5;387(10022):968-977
pubmed: 26703889
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Cancer Res. 2009 Jun 1;69(11):4894-903
pubmed: 19487300
N Engl J Med. 2011 Feb 10;364(6):501-13
pubmed: 21306237
Cancer Lett. 2014 Nov 28;354(2):220-6
pubmed: 25168479
Cancer Res. 2009 Sep 1;69(17):6987-94
pubmed: 19706755
Cancer Treat Rev. 2021 Sep;99:102261
pubmed: 34332293
Indian J Pharmacol. 2020 Sep-Oct;52(5):402-413
pubmed: 33283772
J Transl Med. 2016 May 03;14(1):113
pubmed: 27142424
Br J Cancer. 2005 Jan 17;92(1):94-101
pubmed: 15558070
Neuroendocrinology. 2013;97(1):45-56
pubmed: 22538258
J Neurooncol. 2011 Nov;105(2):325-35
pubmed: 21523485
J Clin Oncol. 2022 Oct 19;:101200JCO2201013
pubmed: 36260828
Nat Rev Clin Oncol. 2010 Aug;7(8):455-65
pubmed: 20531380
BMC Cancer. 2016 Aug 18;16:645
pubmed: 27538897
Cancer Lett. 2017 Aug 1;400:282-292
pubmed: 28189534
J Neuroendocrinol. 2022 Oct;34(10):e13189
pubmed: 36306196
Br J Cancer. 2011 Mar 29;104(7):1067-70
pubmed: 21386841
Recent Results Cancer Res. 2010;180:165-83
pubmed: 20033383
Cancer Res. 2002 Dec 1;62(23):6938-43
pubmed: 12460910
Target Oncol. 2012 Jun;7(2):93-8
pubmed: 22592949
J Clin Med. 2019 Aug 15;8(8):
pubmed: 31443197
Lancet. 2011 Dec 10;378(9808):2005-2012
pubmed: 22119496
Pharmacogenomics J. 2019 Dec;19(6):556-563
pubmed: 30723313
J Biochem. 2013 Mar;153(3):243-9
pubmed: 23293323
Semin Radiat Oncol. 2003 Jul;13(3):176-81
pubmed: 12903007
Gastroenterology. 2003 Oct;125(4):1094-104
pubmed: 14517793
Endocrine. 2019 Aug;65(2):460-467
pubmed: 31037707
Cancer Res. 2000 Apr 1;60(7):1878-86
pubmed: 10766175
Stem Cells Dev. 2012 Mar 1;21(4):503-6
pubmed: 21933025
J Clin Oncol. 1995 Jun;13(6):1486-92
pubmed: 7751896